![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Braintree Laboratories |
Information provided by: | Braintree Laboratories |
ClinicalTrials.gov Identifier: | NCT00583713 |
To evaluate and compare the effects on safety measures and clinical chemistry after BLI800 in two groups of patients and one group of healthy controls. The patient groups will be those with mild or moderate hepatic impairment or moderate renal disease.
Condition | Intervention | Phase |
Colonoscopy Bowel Preparation |
Drug: BLI-800 |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Parallel Assignment |
Estimated Enrollment: | 18 |
Study Start Date: | August 2007 |
Study Completion Date: | June 2008 |
Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Experimental |
Drug: BLI-800
BLI-800
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Are male or female adults who are:
Exclusion Criteria:
Responsible Party: | Braintree Laboratories, Inc. ( Russell Pelham, Ph.D. ) |
Study ID Numbers: | BLI-800-202 |
First Received: | December 20, 2007 |
Last Updated: | July 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00583713 |
Health Authority: | United States: Food and Drug Administration |
![]() |